Malcolm A. Martin - Concepedia

Author

Malcolm A. Martin

National Institute of Allergy and Infectious Diseases ORCID

Also Known As

John R. Mascola, M A Martin, M. A. Martin, M. Martin, M.A. Martin, MALCOLM A. MARTIN, Malcolm A Martin, Malcolm A. Martin, Malcolm Martin, Martin, Malcolm A.

Publications

6.6K

Citations

H-Index

Concepts

All Affiliations

National Institute of Allergy and Infectious Diseases National Institutes of Health Rockefeller University National Cancer Institute Laboratory of Molecular Genetics

About

Malcolm A. Martin is an author at National Institute of Allergy and Infectious Diseases specializing in medicine, virology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	37	4K
2	Natural Sciences	5	5	360
3	Engineering	1	1	82
4	Allergy	1	1	87
5	Biology	1	1	19

Malcolm A. Martin

Publications

6.1K

Citations

H-Index

Page 1

	Year	Citations
Administration of an Anti-CD8 Monoclonal Antibody Interferes with the Clearance of Chimeric Simian/Human Immunodeficiency Virus during Primary Infections of Rhesus Macaques Tetsuro Matano, Riri Shibata, Christine Siemon, Journal of Virology	1998	485
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia Masashi Shingai, Yoshiaki Nishimura, Florian Klein, Nature VaccinationViral PersistencePathogenesisImmunologyViral Pathogenesis	2013	450
Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4 <sup>+</sup> T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans Tatsuhiko Igarashi, Charles R. Brown, Yasuyuki Endo, Proceedings of the National Academy of Sciences Principal ReservoirViral ReplicationTissue MacrophageImmunologyViral Pathogenesis	2001	351
Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques Masashi Shingai, Olivia K. Donau, Ronald J. Plishka, The Journal of Experimental Medicine ImmunologyImmunodominanceImmunotherapeuticsImmunotherapyPlasma Neutralization Titers	2014	327
Early antibody therapy can induce long-lasting immunity to SHIV Yoshiaki Nishimura, Rajeev Gautam, Tae‐Wook Chun, Nature Veterinary VaccineImmunologyVirologyHumoral ImmunityImmunotherapy	2017	307
A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges Rajeev Gautam, Yoshiaki Nishimura, Amarendra Pegu, Nature VaccinationShiv ChallengesHuman RetrovirusImmunologyAntiviral Therapy	2016	306
HIV Vaccine Research: The Way Forward Anthony S. Fauci, Margaret I. Johnston, Carl W. Dieffenbach, Science VaccinationVaccine DevelopmentNeurovirologyVaccine TargetImmunology	2008	237
Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization Ivelin S. Georgiev, Nicole A. Doria‐Rose, Tongqing Zhou, Science Viral DiagnosticsImmunologyPathologyImmunotherapyNeutralization Fingerprints	2013	223
The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity John M. Leonard, Colleen Parrott, Alicia Buckler‐White, Journal of Virology Viral ReplicationHuman RetrovirusPathogenesisImmunologyNf-kappa B	1989	211
Contribution of NF-kappa B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types Elizabeth K. Ross, Alicia Buckler‐White, Arnold B. Rabson, Journal of Virology Viral ReplicationVirus ProgenyImmunologyMolecular BiologyVirus Stocks	1991	188

Page 1